What it is
Obstructive sleep apnea (OSA), repeated collapse of the upper airway during sleep, is common and is associated with reduced quality of life and more cardiometabolic disease. ATTAIN-OSA was two 52-week, phase 3, double-blind, placebo-controlled trials at 66 sites in the US, Argentina, Brazil, China, the Czech Republic, Germany, Japan, Mexico and Taiwan, in adults with moderate to severe OSA and a body mass index of 27 or higher. Trial 1 randomized 363 patients not using positive airway pressure (PAP) and trial 2 randomized 349 patients who were, each to once-daily orforglipron at the maximum tolerated dose or to placebo. From baseline averages of 50.7 and 57.6 events per hour, the apnea-hypopnea index (AHI, breathing pauses and shallow breaths per hour of sleep) fell by 17.8 with orforglipron against 4.5 with placebo in trial 1 (difference -13.2) and by 17.3 against 5.3 in trial 2 (difference -12.0) at 52 weeks, both statistically significant. Of 7 key secondary end points, which included hypoxic burden, a sleep-related impairment score and C-reactive protein, 6 were statistically significant, favoring orforglipron.
Why it matters
A daily tablet lowered breathing interruptions in adults with moderate to severe sleep apnea and obesity or overweight, both off and on a PAP machine. The authors present the results as evidence for oral orforglipron to improve sleep-disordered breathing in adults with moderate to severe OSA and obesity or overweight.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underObstructive Sleep Apnea Research, Apelin-related biomedical research, Sleep and related disorders